首页> 外文期刊>Biochemica >Gene-Expression Analysis of TP, DPD, and TS Using the LightCycler mRNA Quantification Kits~(PLUS)
【24h】

Gene-Expression Analysis of TP, DPD, and TS Using the LightCycler mRNA Quantification Kits~(PLUS)

机译:使用LightCycler mRNA定量试剂盒〜(PLUS)分析TP,DPD和TS的基因表达

获取原文
获取原文并翻译 | 示例
           

摘要

In human cells, the enzymes thymidin phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), and thymidylate synthase (TS) play a pivotal role in the metabolism of pyrimidines. In cancer disease medical care, the cytotoxic compound 5-fluorouracil (5-FU) is the standard chemotherapy treatment for a wide range of solid tumors. Attempts to increase the efficacy and tolerability of fluoropyrimidine treatment has led to the development of Capecitabine (Xeloda), a fluoropyrimidine drug from Roche Pharmaceuticals. Capecitabine is not cytotoxic unless it is activated to 5-FU by TP a three-step mechanism. Therefore, it has several advantages over ordinary 5-FU by treatment [1,2].
机译:在人类细胞中,胸苷磷酸化酶(TP),二氢嘧啶脱氢酶(DPD)和胸苷酸合酶(TS)酶在嘧啶的代谢中起关键作用。在癌症疾病的医疗保健中,细胞毒性化合物5-氟尿嘧啶(5-FU)是用于多种实体瘤的标准化学疗法。试图增加氟嘧啶治疗的功效和耐受性的尝试导致了卡培他滨(希罗达)的开发,这是一种来自罗氏制药公司的氟嘧啶药物。卡培他滨只有通过三步机制被TP激活成5-FU才具有细胞毒性。因此,通过治疗[1,2],它具有比普通5-FU更好的优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号